Pan Cancer T Secures EUR 10M to Advance First-in-Human Trial of PCT1:CO-STIM in TNBC December 15, 2025
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer December 15, 2025
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline Including OMNI-EGFR Inhibitor for NSCLC December 15, 2025
Immutep and Dr. Reddy’s enter Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 15, 2025
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch Ph 2a dose-expansion trial with TTX-MC138 December 15, 2025
Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma December 15, 2025
New Analyses of DUBLIN-3 Ph 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for NonSq EGFR WT NSCLC and a Reduction in Brain Mets Compared to Docetaxel Announced December 15, 2025
Updated Efficacy Data of Ivonescimab Combined with Chemo as 1L Treatment for TNBC Presented December 15, 2025
FAILED TRIAL: Ph 3 STAR-221 study of domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility December 15, 2025
Conditional Marketing Authorization Recommendation from EMA Received for ANKTIVA® with BCG for NMIBC Carcinoma in Situ December 15, 2025
FDA grants Orphan Drug Designation for AJ1-11095 for the Treatment of Myelofibrosis December 15, 2025
FDA Grants Priority Review to supplemental BLA for Opdivo® + Chemo Combo for Classical Hodgkin Lymphoma December 15, 2025
Cadonilimab Receives FDA Clearance for Global Ph 3 1L Gastric Cancer Trial vs. Nivolumab December 15, 2025
FDA approves AKEEGA® for BRCA2m metastatic CSPC with 54% reduction in disease progression vs SOC December 15, 2025
